Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

CVR Energy misses Q1 2026 forecasts significantly and reports large net loss

CVR Energy reported Q1 2026 EPS of -1.24 USD, well below the expected -0.38 USD, while revenue of 1.98 billion USD exceeded estimates. The company recorded a consolidated net loss of 160 million USD and adjusted EBITDA of 37 million USD. Results were hurt by unrealized losses on derivative transactions and high RIN prices; the stock fell 1.58% in premarket trading. For Q2 2026 CVR expects throughput of 200,000–215,000 bpd and direct operating costs of 110–120 million USD; strategic adjustments to the crude slate are intended to improve margins. » Plus sur de.investing.com
CVR Energy hits 52-week high and offers high dividend yield

CVR Energy’s stock rose to $33.25, marking a 52-week high and bringing market capitalization to about $3.33 billion. The yield is 11.49% and the company has paid dividends for 12 consecutive years. Despite a strong price gain of 39.4% over the past year (58.45% in six months), CVR reported an adjusted loss per share of $0.23 in Q2/2025 (expectation: -$0.06), but beat revenue expectations with $1.76 billion. Analyst notes indicate the stock may be trading above its fair value; gross profit margin remained weak at 1.63%. » Plus sur de.investing.com
CVR Energy reaches 52-week high at 32.67 USD

CVR Energy’s stock rose to a 52-week high of 32.67 USD and has gained 70.7% over the past six months; year-to-date the increase is 49.4%. InvestingPro cites a dividend yield of 11.35% and notes 12 consecutive years of dividend payments, but considers the stock to be above its fair value. For Q2 2025 the company reported an adjusted loss per share of 0.23 USD (expectation: -0.06 USD) on revenue of 1.76 billion USD (expectation: 1.68 billion USD), after which the stock fell sharply in after-hours trading. » Plus sur de.investing.com

Données financières de l'entreprise

Au cours de la dernière année, CVR Medical a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -1,58 M €

(EUR)	2021	YoY
Chiffre d'affaires	0	-
Bénéfice brut	-215,45	7,54 %
Bénéfice net	-1,58 M	1 012,76 %
EBITDA	-602,63 k	1 587,74 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	925,25 €
Nombre d'actions	107,2 M
Plus haut/bas sur 52 semaines	0,0000086 € - 0,0000009 €
Dividendes	Non
Bêta	1,91
Ratio P/E	0,00
Ratio PEG	0,00
Ratio P/B	0,00
Ratio P/S	0,00

Profil de l'entreprise

CVR Medical Corp. ist ein Unternehmen des Gesundheitswesens, das sich mit der Erforschung und Entwicklung von Technologien zur Analyse von Unterschall-, Infraschall- und Niederfrequenz-Schallwellen für den Gesundheitssektor befasst. Das Unternehmen bietet ein Gerät zum Scannen von Karotisstenosen an, ein Diagnoseinstrument zur Erkennung und Messung von Karotisstenosen in den Arterien. Es bietet seine Produkte für Patienten, Kostenträger und Gesundheitsdienstleister an. CVR Medical Corp. wurde 1980 gegründet und hat seinen Hauptsitz in North Vancouver, Kanada.